证券代码：600535 证券简称：天士力 编号：临 2025-043 号 天士力医药集团股份有限公司 关于全资子公司药品托拉塞米注射液获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，天士力医药集团股份有限公司（以下简称"公司"）之全资子公司江 苏天士力帝益药业有限公司（以下简称"江苏帝益"）收到国家药品监督管理局 颁发的关于托拉塞米注射液（以下简称"该药品"）的《药品注册证书》，现将 相关情况公告如下： 一、药品的基本情况 药品批准文号：国药准字 H20254226、国药准字 H20254225 上市许可持有人：江苏天士力帝益药业有限公司 生产企业：成都市海通药业有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品的相关信息 托拉塞米注射液适用于需要迅速利尿或不能口服利尿的充血性心力衰竭、肝 硬化腹水、肾脏疾病所致的水肿患者。托拉塞米注射液原研药于 1991 年在欧盟 获批上市，持证商为 Berlin-C ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 15% [4][23]. Core Views - The company has shown stable revenue growth despite external industry challenges, with Q1 2025 revenue at 2.055 billion yuan, a year-on-year increase of 0.30%. The net profit attributable to shareholders was 314 million yuan, up 6.47% year-on-year, while the net profit after deducting non-recurring items decreased by 19.54% [2][8]. - The company is focusing on enhancing R&D capabilities and modernizing traditional Chinese medicine, with expectations for stable growth in the traditional Chinese medicine sector and new product introductions in chemical and biological pharmaceuticals [1][10][11]. - The strategic integration with China Resources is progressing well, which is anticipated to strengthen the company's competitive position in the market [12]. Financial Performance Summary - For Q1 2025, the company achieved a revenue of 2.055 billion yuan, with a net profit of 314 million yuan. The core pharmaceutical segment generated 1.842 billion yuan in revenue, reflecting a 1.83% increase year-on-year [2][9]. - The company’s gross margin for Q1 2025 was 66.61%, a slight decrease of 0.55 percentage points year-on-year, indicating stable profitability despite pricing pressures [13]. - The forecast for revenue from 2025 to 2027 is projected to be 9.001 billion yuan, 9.539 billion yuan, and 10.129 billion yuan, respectively, with corresponding net profits of 1.074 billion yuan, 1.216 billion yuan, and 1.386 billion yuan, reflecting growth rates of 12.4%, 13.3%, and 14.0% [16].

Core Insights - Tianjin Tasly Pharmaceutical Group has been recognized in the "2025 Future Medical 100 Strong" list for its innovative capabilities in the healthcare sector, showcasing its role as a benchmark for traditional Chinese medicine innovation [1] Group 1: R&D Innovation - The company employs a "four-in-one" R&D model, with a pipeline of 98 products under development, including modern Chinese medicine, biological drugs, and chemical drugs for 2024 [3] - Key products in the innovation pipeline include three traditional Chinese medicine formulations in the production application stage and 17 products in clinical phases II and III [3] - In the biological drug sector, the product "Puyouke" has submitted a production application, with phase III clinical results published in the international journal "The Lancet Neurology" [3] Group 2: Intelligent Manufacturing - Tasly has established a modern intelligent manufacturing system recognized by the Ministry of Industry and Information Technology, ensuring quality traceability from raw material planting to finished product delivery [4] - The company has developed a high-speed pill-making machine that enhances drug loading and dissolution speed through electromagnetic suspension and cryogenic technology [4] Group 3: Market Innovation - The company has created a comprehensive product structure with modern Chinese medicine at its core, supported by high-quality chemical and biological drugs, covering various treatment areas [5] - Tasly has built a specialized promotion network across most regions of the country, ensuring coverage of grassroots medical institutions, with 14 products included in 20 guidelines and 16 clinical consensus applications in 2024 [5] - The company has received multiple awards for its digital marketing efforts, including the "Annual Digital Marketing Star" and "Social Public Welfare Award" for its innovative digital marketing platform [5]

Core Viewpoint - The legal opinion confirms that the procedures for convening and holding the third extraordinary general meeting of Tianjin Tianshili Pharmaceutical Group Co., Ltd. are in compliance with relevant laws and regulations, and the voting results are valid [1][2][4]. Group 1: Meeting Procedures - The notice for the meeting was issued on April 29, 2025, detailing the time, location, and agenda [2]. - The meeting was held on May 14, 2025, using a combination of on-site and online voting methods [2][3]. - The voting period for online participation was specified, and the procedures followed were in accordance with legal and regulatory requirements [2][3]. Group 2: Attendance and Qualifications - The meeting was attended by shareholders and their proxies, with verification of their identities conducted by the Shanghai Stock Exchange [3]. - The board of directors served as the convener of the meeting, and the qualifications of attendees were deemed valid [3]. Group 3: Voting Procedures and Results - Voting was conducted through both on-site and online methods, with results compiled after the voting concluded [4]. - The first resolution, requiring a two-thirds majority, was passed, while the second resolution, needing a simple majority, was also approved [4]. - The voting process and results were confirmed to be in compliance with legal and regulatory standards [4].

致：天士力医药集团股份有限公司 内蒙古建中律师事务所（以下称"本所"）受天士力医药集团股份有限公司 （以下称"贵公司"或"公司"）的委托，指派本所执业律师郭瑞鹏、张辛羽（以 下称"本所经办律师"）出席了贵公司 2025 年第三次临时股东大会（以下称"本 次股东大会"），并根据《中华人民共和国证券法》（以下称"《证券法》"）、 《中华人民共和国公司法》（以下称"《公司法》"）和中国证监会《上市公司 股东大会规则》（以下称"《股东大会规则》"）等法律、法规和规范性文件以 及《天士力医药集团股份有限公司章程》（以下称"《章程》"）的规定，就本 次股东大会的召集、召开程序、出席会议人员资格以及表决程序和表决结果的合 法有效性出具本法律意见书。 为出具本法律意见书，本所经办律师已对本次股东大会所涉及的有关事项及 文件资料进行了必要的核查和验证，且贵公司已对前述资料的真实性和准确性向 本所作了保证。 本法律意见书仅供贵公司为本次股东大会的适当目的使用，不得被任何人用 于其他任何目的。 本所同意贵公司将本法律意见书作为贵公司本次股东大会公告材料，随其他 文件一同公开披露，并对贵公司引用的本法律意见承担相应的法律责任。 内蒙 ...

证券代码：600535 证券简称：天士力 编号：临2025-042号 天士力医药集团股份有限公司 2025年第三次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 1、公司在任董事15人，出席13人，董事王亮先生、王克先生因工作原因未能出席本 次股东大会； 2、公司在任监事5人，出席4人，监事高展先生因工作原因未能出席本次股东大会； 3、董事会秘书于杰先生出席本次股东大会；财务总监魏洁女士列席会议。 (一) 股东大会召开的时间：2025 年 5 月 14 日 (二) 股东大会召开的地点：天士力医药集团股份有限公司会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 851 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 706,427,270 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 49.7 ...

2025 年 5 月 14 日 2025 年第三次临时股东大会会议资料 2025 年第三次临时股东大会会议资料 天士力医药集团股份有限公司 2025 年第三次临时股东大会会议资料 天士力医药集团股份有限公司 2025 年第三次临时股东大会议程 一、会议时间： 现场会议召开时间：2025 年 5 月 14 日 15 点 30 分 网络投票系统及投票时间： 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2025 年 5 月 14 日 至 2025 年 5 月 14 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东大会 召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票平台的 投票时间为股东大会召开当日的 9:15-15:00。 （四）宣读议案并请股东针对议案发表意见 | 序号 | | | 议案名称 | | --- | --- | --- | --- | | 非累积投票议案 | | | | | 1 | 关于增加经营范围并修订《公司章程》的议案 | | | | 2 | 关于公司 | 2025 | 年度担保预计的议 ...

Meeting Overview - The shareholders' meeting was held on May 7, 2025, at the Tianjin Beichen Technology Park [1] - The meeting was conducted with both on-site and online voting, presided over by the chairwoman, Zhou Hui [1] Attendance - Out of 15 current directors, 12 attended the meeting, while three were absent due to work commitments [2] - All 5 current supervisors attended the meeting, along with the board secretary and the financial director [2] Proposal Review - A proposal to increase the expected daily related transactions for 2025 was approved [3] - The voting for the proposal was a non-cumulative voting process, requiring a simple majority from the attending shareholders [3][4] Legal Witnessing - The meeting was legally witnessed by Inner Mongolia Jianzhong Law Firm, with lawyers Liu Hong and Zhang Xinyu present [5] - The legal opinion confirmed that the meeting's procedures and voting results were in compliance with relevant laws and regulations [5]

2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 证券代码：600535 证券简称：天士力 编号：临2025-041号 天士力医药集团股份有限公司 (一) 股东大会召开的时间：2025 年 5 月 7 日 | 1、出席会议的股东和代理人人数 | 1,049 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 300,832,102 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 30.0548 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议采取现场投票与网络投票相结合的方式召开及表决。会议由公司董事 会召集，根据《公司章程》有关规定，由董事长周辉女士现场主持本次会议。会议 的召集、召开符合有关法律、法规、规章和《公司章程》的规定。 (五) 公司董事、监事和董事会秘书的出席情况 1、公司在任董事15人，出席12人， ...

内蒙古建中律师事务所 关于天士力医药集团股份有限公司 2025 年第二次临时股东大会的法律意见书 2025 内建中券意字第 11 号 致：天士力医药集团股份有限公司 内蒙古建中律师事务所（以下称"本所"）受天士力医药集团股份有限公司 （以下称"贵公司"或"公司"）的委托，指派本所执业律师刘弘、张辛羽（以 下称"本所经办律师"）出席了贵公司 2025 年第二次临时股东大会（以下称"本 次股东大会"），并根据《中华人民共和国证券法》（以下称"《证券法》"）、 《中华人民共和国公司法》（以下称"《公司法》"）和中国证监会《上市公司 股东大会规则》（以下称"《股东大会规则》"）等法律、法规和规范性文件以 及《天士力医药集团股份有限公司章程》（以下称"《章程》"）的规定，就本 次股东大会的召集、召开程序、出席会议人员资格以及表决程序和表决结果的合 法有效性出具本法律意见书。 为出具本法律意见书，本所经办律师已对本次股东大会所涉及的有关事项及 文件资料进行了必要的核查和验证，且贵公司已对前述资料的真实性和准确性向 本所作了保证。 本法律意见书仅供贵公司为本次股东大会的适当目的使用，不得被任何人用 于其他任何目的。 本所同 ...